<i>ICOS</i> gene polymorphisms in B-cell chronic lymphocytic leukemia in the Polish population
There is strong evidence that altered immunological function entails an increased risk of B-cell chronic lymphocytic leukemia (B-CLL). The main mechanism of an anti-tumor response depends on T-cell activation. Unlike the constitutively expressed CD28, inducible costimulatory molecule (ICOS) is expre...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Via Medica
2011-04-01
|
| Series: | Folia Histochemica et Cytobiologica |
| Subjects: | |
| Online Access: | http://czasopisma.viamedica.pl/fhc/article/view/4143 |
| _version_ | 1818941696028704768 |
|---|---|
| author | Irena Frydecka Kazimierz Kuliczkowski Dariusz Woszczyk Marek Kielbinski Dariusz Wolowiec Anna Tomkiewicz Anna Jedynak Lidia Karabon |
| author_facet | Irena Frydecka Kazimierz Kuliczkowski Dariusz Woszczyk Marek Kielbinski Dariusz Wolowiec Anna Tomkiewicz Anna Jedynak Lidia Karabon |
| author_sort | Irena Frydecka |
| collection | DOAJ |
| description | There is strong evidence that altered immunological function entails an increased risk of B-cell chronic lymphocytic leukemia (B-CLL). The main mechanism of an anti-tumor response depends on T-cell activation. Unlike the constitutively expressed CD28, inducible costimulatory molecule (ICOS) is expressed on the T-cell surface after activation. ICOS enhances all the basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, the upregulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B cells. ICOS is essential for both efficient interaction between T and B cells and normal antibody responses to T cell-dependent antigens. It does not upregulate the production of interleukin-2, but superinduces the synthesis of interleukin-10. Our previous results indicated the <i>ICOS</i> gene has a role as a susceptibility locus to B-CLL. Therefore an extended study was undertaken to evaluate the association between four <i>ICOS</i> polymorphisms (which were recently described as functional ones) and susceptibility to B-CLL in the Polish population. A case-control study of 296 individuals, including 146 B-CLL patients, was conducted on four polymorphisms in the <i>ICOS</i> gene. Genotyping of the polymorphisms ICOS ISV1+173T>C (rs10932029), ICOSc.1624C>T (rs10932037), ICOSc.2373G>C (rs4675379), and ICOSc.602A>C (rs10183087) was carried out using allelic discrimination methods with the TaqMan&#174; SNP Genotyping Assay. There were no statistically significant differences in the allele, genotype, or haplotype distributions between B-CLL patients and healthy controls for any of the investigated polymorphic markers in the ICOS gene. However, we noted that patients carrying genotype ICOS ISV1+173T>C [TT], ICOSc.602A>C [AA], ICOSc.1624C>T [CC], and ICOSc.2373G>C [GG] have a decreased frequency of progression to a higher Rai stage during 60-month follow-up (21.35% vs. 40.8%, p = 0.013) compared to other individuals. This indicates that the investigated polymorphisms do not modulate the risk of B-CLL in the Polish population, but are associated with disease dynamics, in particular with the time to Rai stage progression. <i>(Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 1, pp. 49&#8211;54) |
| first_indexed | 2024-12-20T06:59:38Z |
| format | Article |
| id | doaj.art-c5a22fb4d906472cafe526e037109301 |
| institution | Directory Open Access Journal |
| issn | 0239-8508 1897-5631 |
| language | English |
| last_indexed | 2024-12-20T06:59:38Z |
| publishDate | 2011-04-01 |
| publisher | Via Medica |
| record_format | Article |
| series | Folia Histochemica et Cytobiologica |
| spelling | doaj.art-c5a22fb4d906472cafe526e0371093012022-12-21T19:49:14ZengVia MedicaFolia Histochemica et Cytobiologica0239-85081897-56312011-04-01491495410.5603/4143<i>ICOS</i> gene polymorphisms in B-cell chronic lymphocytic leukemia in the Polish populationIrena FrydeckaKazimierz KuliczkowskiDariusz WoszczykMarek KielbinskiDariusz WolowiecAnna TomkiewiczAnna JedynakLidia KarabonThere is strong evidence that altered immunological function entails an increased risk of B-cell chronic lymphocytic leukemia (B-CLL). The main mechanism of an anti-tumor response depends on T-cell activation. Unlike the constitutively expressed CD28, inducible costimulatory molecule (ICOS) is expressed on the T-cell surface after activation. ICOS enhances all the basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, the upregulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B cells. ICOS is essential for both efficient interaction between T and B cells and normal antibody responses to T cell-dependent antigens. It does not upregulate the production of interleukin-2, but superinduces the synthesis of interleukin-10. Our previous results indicated the <i>ICOS</i> gene has a role as a susceptibility locus to B-CLL. Therefore an extended study was undertaken to evaluate the association between four <i>ICOS</i> polymorphisms (which were recently described as functional ones) and susceptibility to B-CLL in the Polish population. A case-control study of 296 individuals, including 146 B-CLL patients, was conducted on four polymorphisms in the <i>ICOS</i> gene. Genotyping of the polymorphisms ICOS ISV1+173T>C (rs10932029), ICOSc.1624C>T (rs10932037), ICOSc.2373G>C (rs4675379), and ICOSc.602A>C (rs10183087) was carried out using allelic discrimination methods with the TaqMan&#174; SNP Genotyping Assay. There were no statistically significant differences in the allele, genotype, or haplotype distributions between B-CLL patients and healthy controls for any of the investigated polymorphic markers in the ICOS gene. However, we noted that patients carrying genotype ICOS ISV1+173T>C [TT], ICOSc.602A>C [AA], ICOSc.1624C>T [CC], and ICOSc.2373G>C [GG] have a decreased frequency of progression to a higher Rai stage during 60-month follow-up (21.35% vs. 40.8%, p = 0.013) compared to other individuals. This indicates that the investigated polymorphisms do not modulate the risk of B-CLL in the Polish population, but are associated with disease dynamics, in particular with the time to Rai stage progression. <i>(Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 1, pp. 49&#8211;54)http://czasopisma.viamedica.pl/fhc/article/view/4143ICOSpolymorphismsB-CLL |
| spellingShingle | Irena Frydecka Kazimierz Kuliczkowski Dariusz Woszczyk Marek Kielbinski Dariusz Wolowiec Anna Tomkiewicz Anna Jedynak Lidia Karabon <i>ICOS</i> gene polymorphisms in B-cell chronic lymphocytic leukemia in the Polish population Folia Histochemica et Cytobiologica ICOS polymorphisms B-CLL |
| title | <i>ICOS</i> gene polymorphisms in B-cell chronic lymphocytic leukemia in the Polish population |
| title_full | <i>ICOS</i> gene polymorphisms in B-cell chronic lymphocytic leukemia in the Polish population |
| title_fullStr | <i>ICOS</i> gene polymorphisms in B-cell chronic lymphocytic leukemia in the Polish population |
| title_full_unstemmed | <i>ICOS</i> gene polymorphisms in B-cell chronic lymphocytic leukemia in the Polish population |
| title_short | <i>ICOS</i> gene polymorphisms in B-cell chronic lymphocytic leukemia in the Polish population |
| title_sort | lt i gt icos lt i gt gene polymorphisms in b cell chronic lymphocytic leukemia in the polish population |
| topic | ICOS polymorphisms B-CLL |
| url | http://czasopisma.viamedica.pl/fhc/article/view/4143 |
| work_keys_str_mv | AT irenafrydecka ltigticosltigtgenepolymorphismsinbcellchroniclymphocyticleukemiainthepolishpopulation AT kazimierzkuliczkowski ltigticosltigtgenepolymorphismsinbcellchroniclymphocyticleukemiainthepolishpopulation AT dariuszwoszczyk ltigticosltigtgenepolymorphismsinbcellchroniclymphocyticleukemiainthepolishpopulation AT marekkielbinski ltigticosltigtgenepolymorphismsinbcellchroniclymphocyticleukemiainthepolishpopulation AT dariuszwolowiec ltigticosltigtgenepolymorphismsinbcellchroniclymphocyticleukemiainthepolishpopulation AT annatomkiewicz ltigticosltigtgenepolymorphismsinbcellchroniclymphocyticleukemiainthepolishpopulation AT annajedynak ltigticosltigtgenepolymorphismsinbcellchroniclymphocyticleukemiainthepolishpopulation AT lidiakarabon ltigticosltigtgenepolymorphismsinbcellchroniclymphocyticleukemiainthepolishpopulation |